ArticleClinical kidney journal2017
Clinical proteomics in kidney disease as an exponential technology: heading towards the disruptive phase.
Article in Clinical kidney journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 29 citations in OpenAlex.
- Integrating kidney imaging for risk prediction, therapeutic monitoring, and prognostication across the kidney disease spectrum: a review of emerging evidence.Clinical kidney journal · 2026Review
- Preventing chronic kidney disease and maintaining kidney health: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.Kidney international · 2025Article
- Targeted Analysis of Serum and Urinary Metabolites for Early Chronic Kidney Disease.International journal of molecular sciences · 2025Article
- The impact of population ageing on the burden of chronic kidney disease.Nature reviews. Nephrology · 2024Review
- Prognostic and therapeutic monitoring value of plasma and urinary cytokine profile in primary membranous nephropathy: the STARMEN trial cohort.Clinical kidney journal · 2024Article
- Albuminuria, Forgotten No More: Underlining the Emerging Role in CardioRenal Crosstalk.Journal of clinical medicine · 2024Review
- CKD Urine Metabolomics: Modern Concepts and Approaches.Pathophysiology : the official journal of the International Society for Pathophysiology · 2023Review
- Novel strategies in nephrology: what to expect from the future?Clinical kidney journal · 2023Review
- Benchmarking CKD: incidence of CKD in a European country with low prevalence of CKD and kidney replacement therapy.Clinical kidney journal · 2022Article
- RICORS2040: the need for collaborative research in chronic kidney disease.Clinical kidney journal · 2022Article
- Milestones of Precision Medicine: An Innovative, Multidisciplinary Overview.Molecular diagnosis & therapy · 2021Review
- Hypertensive nephropathy: a major roadblock hindering the advance of precision nephrology.Clinical kidney journal · 2020Article
- Klotho, the elusive kidney-derived anti-ageing factor.Clinical kidney journal · 2020Article
- Review
- The chaos of hypertension guidelines for chronic kidney disease patients.Clinical kidney journal · 2019Article
- Magnetic resonance imaging biomarkers for chronic kidney disease: a position paper from the European Cooperation in Science and Technology Action PARENCHIMA.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2018Article
- Establishing the presence or absence of chronic kidney disease: Uses and limitations of formulas estimating the glomerular filtration rate.World journal of methodology · 2017Review
- Article
- CKD: The burden of disease invisible to research funders.Nefrologia : publicacion oficial de la Sociedad Espanola NefrologiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Exponential technologies double in power or processing speed every year, whereas their cost halves. Deception and disruption are two key stages in the development of exponential technologies. Deception occurs when, after initial introduction, technologies are dismissed as irrelevant, while they continue to progress, perhaps not as fast or with so many immediate practical applications as initially thought. Twenty years after the first publications, clinical proteomics is still not available in most hospitals and some clinicians have felt deception at unfulfilled promises. However, there are indications that clinical proteomics may be entering the disruptive phase, where, once refined, technologies disrupt established industries or procedures. In this regard, recent manuscripts in
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.